Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
11.08
-0.55 (-4.73%)
At close: Jun 27, 2025, 4:00 PM
11.08
0.00 (0.00%)
After-hours: Jun 27, 2025, 4:12 PM EDT
Oruka Therapeutics Employees
Oruka Therapeutics had 28 employees as of December 31, 2024.
Employees
28
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,869,730
Market Cap
416.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORKA News
- 5 weeks ago - Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewsWire
- 6 weeks ago - Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewsWire
- 6 months ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - GlobeNewsWire